Arthritis drug baricitinib re-aimed to target diabetic kidney disease
Researchers have presented promising results from a clinical trial of the experimental drug baricitinib in people with diabetic kidney disease...
List view / Grid view
News
Novartis announces new one-year results demonstrating sustained secukinumab efficacy in ankylosing spondylitis patients
10 June 2015 | By Victoria White
Novartis has announced new one-year study results from the MEASURE 2 pivotal Phase III study of secukinumab in ankylosing spondylitis (AS)...
New data on quality-of-life benefits of Simponi in treating patients with nr-axial SpA presented at EULAR 2015
10 June 2015 | By Victoria White
MSD has announced additional data from a subanalysis of the GO-AHEAD study on the effect of Simponi in treating patients with nr-axial SpA...
Glaucoma treatment market value will grow moderately to $3 billion by 2023
10 June 2015 | By Victoria White
The treatment market for glaucoma will rise in value from $2.4 billion in 2013 to approximately $3 billion by 2023 across the seven major markets...
New data shows Enstilar provides rapid itch relief for psoriasis patients
10 June 2015 | By Victoria White
New data shows that aerosol foam Enstilar provided rapid itch relief and improvements in itch-related sleep loss for patients suffering from psoriasis...
Quotient Clinical delivers breakthrough first-in-human program for Corcept Therapeutics
10 June 2015 | By kdm communications
Quotient Clinical, the Translational Pharmaceutics® Company, has announced the successful completion of an Enabled-First-in-Human® (Enabled-FIH) program for US biotech company Corcept Therapeutics Incorporated...
Data from the Orencia Phase 3b AVERT and AMPLE trials to be presented at EULAR 2015
10 June 2015 | By Victoria White
Bristol-Myers Squibb has announced that data from the Orencia Phase 3b AVERT and AMPLE trials will be presented in during the EULAR 2015...
Bayer to sell its Diabetes Care business to Panasonic Healthcare Holdings Co. Ltd.
10 June 2015 | By Victoria White
Bayer has entered into a definitive agreement to sell its Diabetes Care business to Panasonic Healthcare Holdings Co., Ltd., for EUR 1,022 million...
Roche receives US FDA breakthrough therapy designation for ACTEMRA/RoACTEMRA in systemic sclerosis
10 June 2015 | By Victoria White
The FDA has granted Breakthrough Therapy designation status to Roche’s ACTEMRA/RoACTEMRA (tocilizumab) for systemic sclerosis (SSc)...
Data for Celltrion’s biosimilar infliximab CT-P13 presented at EULAR 2015
10 June 2015 | By Victoria White
Data presented at EULAR 2015 show that the effectiveness of Celltrion’s biosimilar infliximab was similar to the RMP in rheumatoid arthritis...
CPhI helps internationalise Japanese and South East Asian markets
10 June 2015 | By Victoria White
UBM EMEA, organiser of CPhI South East Asia and CPhI Japan, has celebrated the closing of two growing Asian events that took place in April this year...
GE showcases Asset Performance Management solution for chemical industry; Up to 30% reduction in maintenance costs thanks to predictive analytics
9 June 2015 | By GE
At the ACHEMA 2015 trade show in Frankfurt, GE showcases applications for use in Asset Performance Management (APM) in the chemical and process industries...
Coulter Partners strengthens US presence with the appointment of Shawn O’Connor at new office in Morristown, NJ
9 June 2015 | By Coulter Partners
Coulter Partners is pleased to announce the appointment of Shawn O’Connor as a Managing Director of their US business...
NICE guidance recommends anti-blood clotting drug apixaban
9 June 2015 | By NICE
NICE has recommended the anti-blood clotting drug apixaban as an option for treating and preventing venous thromboembolism (VTE) in adults...
Carbylan completes enrollment for its Phase 3 trial of Hydros-TA in osteoarthritis
9 June 2015 | By Victoria White
Carbylan Therapeutics has completed enrollment of its COR1.1 Phase 3 pivotal trial of Hydros-TA for the treatment of pain associated with osteoarthritis...
